Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Following a fantastic event, Theolytics was announced the winner of the BioEscalator’s inaugural Pitch Finale, which was kindly supported by Santander Universities UK.

Following on from the success of our Pitch Battle in April, we sought to encourage the peer mentorship within our community. As the BioEscalator ecosystem currently comprises 13 high-growth companies in the early funding stages of seed to post series A, we were keen to utilise this wealth of knowledge and experience to support our companies in the process of raising series A, by matching our top start-ups with mentors from within our company pool. After 3 weeks of training and feedback on their business plans and investor slide decks, Theolytics, who are developing oncolytic viruses as therapeutics, Alchemab Therapeutics, who are utilising native antibodies and a novel platform to discover new therapeutics and Bioarchitech, who are developing novel oncolytic viral therapies, all gave excellent 6 minute pitches to our esteemed judging panel.

The full story is available on the BioEscalator website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.